Pharmacogenetic association study on clopidogrel response in Puerto Rican hispanics with cardiovascular disease: A novel characterization of a Caribbean population

Dagmar F. Hernandez-Suarez, Mariana R. Botton, Stuart A. Scott, Matthew I. Tomey, Mario J. Garcia, Jose M. Wiley, Pedro A. Villablanca, Kyle Melin, Angel Lopez-Candales, Jessicca Y. Renta, Jorge Duconge

Research output: Contribution to journalArticle

Abstract

Introduction: High on-treatment platelet reactivity (HTPR) to clopidogrel imparts an increased risk for ischemic events in adults with coronary artery disease. Platelet reactivity varies with ethnicity and is influenced by both clinical and genetic variables; however, no clopidogrel pharmacogenetic studies with Puerto Rican patients have been reported. Therefore, we sought to identify clinical and genetic determinants of on-treatment platelet reactivity in a cohort of Puerto Rican patients with cardiovascular disease. Methods: We performed a retrospective study of 111 patients on 75 mg/day maintenance dose of clopidogrel. Patients were allocated into 2 groups: Group I, without HTPR; and Group II, with HTPR. Platelet function was measured ex vivo using the VerifyNow® P2Y12 assay and HTPR was defined as P2Y12 reaction units (PRU) ≥230. Genotyping testing was performed using Taqman Genotyping Assays. ® Results: The mean PRU across the cohort was 203±61 PRU (range 8–324), and 42 (38%) patients had HTPR. Multiple logistic regression showed that 27% of the total variation in PRU was explained by a history of diabetes mellitus, hematocrit, CYP2C19*2, and PON1 p.Q192R. Body mass index (odds ratio [OR]=1.15; 95% CI: 1.03–1.27), diabetes mellitus (OR=3.46; 95% CI: 1.05–11.43), hematocrit (OR=0.75; 95% CI: 0.65–0.87), and CYP2C19*2 (OR=4.44; 95% CI: 1.21–16.20) were the only independent predictors of HTPR. Conclusion: Moreover, we propose a predictive model to determine PRU values as measured by VerifyNow P2Y12 assay for the Puerto Rican Hispanic population. This model has the potential to identify Hispanic patients at higher risk for adverse events on clopidogrel.

Original languageEnglish (US)
Pages (from-to)95-106
Number of pages12
JournalPharmacogenomics and Personalized Medicine
Volume11
DOIs
StatePublished - Jun 8 2018

Fingerprint

clopidogrel
Hispanic Americans
Cardiovascular Diseases
Blood Platelets
Population
Odds Ratio
Hematocrit
Therapeutics
Diabetes Mellitus
Pharmacogenomic Testing

Keywords

  • Clopidogrel
  • Genotyping
  • Hispanics
  • Platelet reactivity
  • Puerto Rico

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Pharmacogenetic association study on clopidogrel response in Puerto Rican hispanics with cardiovascular disease : A novel characterization of a Caribbean population. / Hernandez-Suarez, Dagmar F.; Botton, Mariana R.; Scott, Stuart A.; Tomey, Matthew I.; Garcia, Mario J.; Wiley, Jose M.; Villablanca, Pedro A.; Melin, Kyle; Lopez-Candales, Angel; Renta, Jessicca Y.; Duconge, Jorge.

In: Pharmacogenomics and Personalized Medicine, Vol. 11, 08.06.2018, p. 95-106.

Research output: Contribution to journalArticle

Hernandez-Suarez, Dagmar F. ; Botton, Mariana R. ; Scott, Stuart A. ; Tomey, Matthew I. ; Garcia, Mario J. ; Wiley, Jose M. ; Villablanca, Pedro A. ; Melin, Kyle ; Lopez-Candales, Angel ; Renta, Jessicca Y. ; Duconge, Jorge. / Pharmacogenetic association study on clopidogrel response in Puerto Rican hispanics with cardiovascular disease : A novel characterization of a Caribbean population. In: Pharmacogenomics and Personalized Medicine. 2018 ; Vol. 11. pp. 95-106.
@article{da91d3f99173480dbf36ee1af1cd1d72,
title = "Pharmacogenetic association study on clopidogrel response in Puerto Rican hispanics with cardiovascular disease: A novel characterization of a Caribbean population",
abstract = "Introduction: High on-treatment platelet reactivity (HTPR) to clopidogrel imparts an increased risk for ischemic events in adults with coronary artery disease. Platelet reactivity varies with ethnicity and is influenced by both clinical and genetic variables; however, no clopidogrel pharmacogenetic studies with Puerto Rican patients have been reported. Therefore, we sought to identify clinical and genetic determinants of on-treatment platelet reactivity in a cohort of Puerto Rican patients with cardiovascular disease. Methods: We performed a retrospective study of 111 patients on 75 mg/day maintenance dose of clopidogrel. Patients were allocated into 2 groups: Group I, without HTPR; and Group II, with HTPR. Platelet function was measured ex vivo using the VerifyNow{\circledR} P2Y12 assay and HTPR was defined as P2Y12 reaction units (PRU) ≥230. Genotyping testing was performed using Taqman Genotyping Assays. {\circledR} Results: The mean PRU across the cohort was 203±61 PRU (range 8–324), and 42 (38{\%}) patients had HTPR. Multiple logistic regression showed that 27{\%} of the total variation in PRU was explained by a history of diabetes mellitus, hematocrit, CYP2C19*2, and PON1 p.Q192R. Body mass index (odds ratio [OR]=1.15; 95{\%} CI: 1.03–1.27), diabetes mellitus (OR=3.46; 95{\%} CI: 1.05–11.43), hematocrit (OR=0.75; 95{\%} CI: 0.65–0.87), and CYP2C19*2 (OR=4.44; 95{\%} CI: 1.21–16.20) were the only independent predictors of HTPR. Conclusion: Moreover, we propose a predictive model to determine PRU values as measured by VerifyNow P2Y12 assay for the Puerto Rican Hispanic population. This model has the potential to identify Hispanic patients at higher risk for adverse events on clopidogrel.",
keywords = "Clopidogrel, Genotyping, Hispanics, Platelet reactivity, Puerto Rico",
author = "Hernandez-Suarez, {Dagmar F.} and Botton, {Mariana R.} and Scott, {Stuart A.} and Tomey, {Matthew I.} and Garcia, {Mario J.} and Wiley, {Jose M.} and Villablanca, {Pedro A.} and Kyle Melin and Angel Lopez-Candales and Renta, {Jessicca Y.} and Jorge Duconge",
year = "2018",
month = "6",
day = "8",
doi = "10.2147/PGPM.S165805",
language = "English (US)",
volume = "11",
pages = "95--106",
journal = "Pharmacogenomics and Personalized Medicine",
issn = "1178-7066",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Pharmacogenetic association study on clopidogrel response in Puerto Rican hispanics with cardiovascular disease

T2 - A novel characterization of a Caribbean population

AU - Hernandez-Suarez, Dagmar F.

AU - Botton, Mariana R.

AU - Scott, Stuart A.

AU - Tomey, Matthew I.

AU - Garcia, Mario J.

AU - Wiley, Jose M.

AU - Villablanca, Pedro A.

AU - Melin, Kyle

AU - Lopez-Candales, Angel

AU - Renta, Jessicca Y.

AU - Duconge, Jorge

PY - 2018/6/8

Y1 - 2018/6/8

N2 - Introduction: High on-treatment platelet reactivity (HTPR) to clopidogrel imparts an increased risk for ischemic events in adults with coronary artery disease. Platelet reactivity varies with ethnicity and is influenced by both clinical and genetic variables; however, no clopidogrel pharmacogenetic studies with Puerto Rican patients have been reported. Therefore, we sought to identify clinical and genetic determinants of on-treatment platelet reactivity in a cohort of Puerto Rican patients with cardiovascular disease. Methods: We performed a retrospective study of 111 patients on 75 mg/day maintenance dose of clopidogrel. Patients were allocated into 2 groups: Group I, without HTPR; and Group II, with HTPR. Platelet function was measured ex vivo using the VerifyNow® P2Y12 assay and HTPR was defined as P2Y12 reaction units (PRU) ≥230. Genotyping testing was performed using Taqman Genotyping Assays. ® Results: The mean PRU across the cohort was 203±61 PRU (range 8–324), and 42 (38%) patients had HTPR. Multiple logistic regression showed that 27% of the total variation in PRU was explained by a history of diabetes mellitus, hematocrit, CYP2C19*2, and PON1 p.Q192R. Body mass index (odds ratio [OR]=1.15; 95% CI: 1.03–1.27), diabetes mellitus (OR=3.46; 95% CI: 1.05–11.43), hematocrit (OR=0.75; 95% CI: 0.65–0.87), and CYP2C19*2 (OR=4.44; 95% CI: 1.21–16.20) were the only independent predictors of HTPR. Conclusion: Moreover, we propose a predictive model to determine PRU values as measured by VerifyNow P2Y12 assay for the Puerto Rican Hispanic population. This model has the potential to identify Hispanic patients at higher risk for adverse events on clopidogrel.

AB - Introduction: High on-treatment platelet reactivity (HTPR) to clopidogrel imparts an increased risk for ischemic events in adults with coronary artery disease. Platelet reactivity varies with ethnicity and is influenced by both clinical and genetic variables; however, no clopidogrel pharmacogenetic studies with Puerto Rican patients have been reported. Therefore, we sought to identify clinical and genetic determinants of on-treatment platelet reactivity in a cohort of Puerto Rican patients with cardiovascular disease. Methods: We performed a retrospective study of 111 patients on 75 mg/day maintenance dose of clopidogrel. Patients were allocated into 2 groups: Group I, without HTPR; and Group II, with HTPR. Platelet function was measured ex vivo using the VerifyNow® P2Y12 assay and HTPR was defined as P2Y12 reaction units (PRU) ≥230. Genotyping testing was performed using Taqman Genotyping Assays. ® Results: The mean PRU across the cohort was 203±61 PRU (range 8–324), and 42 (38%) patients had HTPR. Multiple logistic regression showed that 27% of the total variation in PRU was explained by a history of diabetes mellitus, hematocrit, CYP2C19*2, and PON1 p.Q192R. Body mass index (odds ratio [OR]=1.15; 95% CI: 1.03–1.27), diabetes mellitus (OR=3.46; 95% CI: 1.05–11.43), hematocrit (OR=0.75; 95% CI: 0.65–0.87), and CYP2C19*2 (OR=4.44; 95% CI: 1.21–16.20) were the only independent predictors of HTPR. Conclusion: Moreover, we propose a predictive model to determine PRU values as measured by VerifyNow P2Y12 assay for the Puerto Rican Hispanic population. This model has the potential to identify Hispanic patients at higher risk for adverse events on clopidogrel.

KW - Clopidogrel

KW - Genotyping

KW - Hispanics

KW - Platelet reactivity

KW - Puerto Rico

UR - http://www.scopus.com/inward/record.url?scp=85057111383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057111383&partnerID=8YFLogxK

U2 - 10.2147/PGPM.S165805

DO - 10.2147/PGPM.S165805

M3 - Article

AN - SCOPUS:85057111383

VL - 11

SP - 95

EP - 106

JO - Pharmacogenomics and Personalized Medicine

JF - Pharmacogenomics and Personalized Medicine

SN - 1178-7066

ER -